Prevention of Platelet Glycoprotein IIb/IIIa Activation by 3,4-Methylenedioxy-β-Nitrostyrene, A Novel Tyrosine Kinase Inhibitor

@article{Wang2006PreventionOP,
  title={Prevention of Platelet Glycoprotein IIb/IIIa Activation by 3,4-Methylenedioxy-$\beta$-Nitrostyrene, A Novel Tyrosine Kinase Inhibitor},
  author={Wei-Ya Wang and Yang chang Wu and Chin‐Chung Wu},
  journal={Molecular Pharmacology},
  year={2006},
  volume={70},
  pages={1380 - 1389}
}
Binding fibrinogen to activated glycoprotein (GP)IIb/IIIa is the final common pathway of platelet aggregation and has become a successful target for antiplatelet therapy. In the present study, we found that a small chemical compound, 3,4-methyl-enedioxy-β-nitrostyrene (MNS), exhibited potent and broad-spectrum inhibitory effects on human platelet aggregation caused by various stimulators. Moreover, addition of MNS to human platelets that had been aggregated by ADP caused a rapid disaggregation… 

Figures and Tables from this paper

Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets.
TLDR
The results suggest that the synergistic antiplatelet effects of exosite-1 inhibitor and PAR4 antagonist are resulted from combined blockade of PAR1 andPAR4 in platelets.
Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis
TLDR
Evidence is provided that 2CP is the first defined platelet antagonist with CLEC-2 binding activity and the augmentation in the therapeutic efficacy of cisplatin by 2CP suggests that a combination of a chemotherapeutic agent and a drug with anti-TCIPA activity such as 2CP may prove clinically effective.
Inhibitory Effects of MNS and BDA-410 on Human Platelet Aggregation
TLDR
A modified model for gel-filtered platelet isolation was developed and used in testing a known cysteine protease inhibitor, BDA-410, and a known tyrosine kinases inhibitor, MNS, and they suggest a role of combination therapy as a potential modality to reduce platelet aggregation and thrombosis in vivo.
αIIbβ3 priming and clustering by orally active and intravenous integrin antagonists
TLDR
The results suggest that the same molecular mechanisms that enable glycoprotein IIb/IIIa inhibitors to bind tightly to the αIIbβ3 receptor and block fibrinogen binding contribute to their ability to perturb the resting integrin's conformation, thus limiting the safety and efficacy of both oral and i.v. integrin antagonists.
...
...

References

SHOWING 1-10 OF 63 REFERENCES
Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
TLDR
GP IIb/IIIa inhibitors can demonstrate an intrinsic activating property, which can result in fibrinogen binding to GP IIb-IIIa and consequently in platelet aggregation, which is a promising new antiplatelet strategy.
Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein IIb/IIIa (IIbβ3) Inhibitors
TLDR
GP IIb/IIIa inhibitors can demonstrate an intrinsic activating property, which can result in fibrinogen binding to GP IIb-IIIa and consequently in platelet aggregation, which is a promising new antiplatelet strategy.
Differential Involvement of Tyrosine and Serine/Threonine Kinases in Platelet Integrin αIIbβ3 Exposure
TLDR
The relative contributions of tyrosine and serine/threonine kinases in α IIb β 3 exposure and aggregation differ among the different agonists, with an exclusive role for PTKs in ADP- and epinephrine-induced responses and a role for bothPTKs and PKCs in responses induced by platelet-activating factor and α-thrombin.
Platelet tyrosine kinases and fibrinogen receptor activation.
TLDR
Genistein and the tyrphostin AG-18 are used in the present study to demonstrate that aggregation inhibition is due to suppression of GPIIb-IIIa activation, and it is shown that protein tyrosine kinase activity is necessary for agonist-induced activation of GP IIb- IIIa.
Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases.
Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses.
TLDR
The results indicate that the blockage by genistein of platelet responses induced by collagen or thromboxane A2 is due to its preventive action on thromboxesine A2 binding to the receptor, rather than via inhibition of protein tyrosine phosphorylation, and that the drug does not appear to be a particularly good inhibitor of tyrosines phosphorylated in intact platelets.
Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
  • J. Leclerc
  • Biology, Medicine
    Critical care medicine
  • 2002
TLDR
The greatest clinical impact of these parenteral agents (used in conjunction with aspirin and heparin) has been in the prevention of ischemic complications after percutaneous coronary intervention and oral agents have yielded disappointing results in the secondary prevention of acute coronary syndromes, and none of them are approved at present.
Differential involvement of tyrosine and serine/threonine kinases in platelet integrin alphaIIbbeta3 exposure.
TLDR
The relative contributions of tyrosine and serine/threonine kinases in alpha(IIb)beta3 exposure and aggregation differ among the different agonists, with an exclusive role for PTKs in ADP- and epinephrine-induced responses and a role for bothPTKs and PKCs in responses induced by platelet-activating factor and alpha-thrombin.
The effects of genistein on platelet function are due to thromboxane receptor antagonism rather than inhibition of tyrosine kinase.
  • A. Mcnicol
  • Biology, Chemistry
    Prostaglandins, leukotrienes, and essential fatty acids
  • 1993
...
...